ArticleFrontiers in immunology2025
Adaptive dynamic ϵ-simulated annealing algorithm for tumor immunotherapy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Personalized cancer treatment requires precise scheduling of multiple therapeutic agents under biological constraints. Optimizing such regimens is especially challenging due to the nonlinear dynamics of tumor-immune interactions and strict feasibility boundaries. This study aims to develop an intelligent optimization approach capable of handling these complexities within a mathematical tumor treatment model. Methods: We propose an Adaptive Dynamic ϵ-Simulated Annealing (ADϵSA) algorithm that integrates a multi-population search framework, dynamic ϵ-constraint control, and boundary-aware mutation mechanisms. The algorithm is applied to an improved tumor immunotherapy model (ITIT), formulated using ordinary differential equations (ODEs) based on established experimental and clinical studies. The model incorporates tumor cells, immune effector cells, and three types of anti-tumor drugs: chemotherapy, immunotherapy, and anti-angiogenic agents. Results: Simulation experiments were conducted on twelve classical benchmark functions to evaluate the convergence performance and robustness of the algorithm. ADϵSA demonstrated strong global search capability, fast convergence, and solution stability. When applied to the ITIT model, the algorithm successfully identified optimal drug dosing schedules that significantly reduced simulated tumor burden-from ~1500 to below 500 cells-while maintaining treatment within physiologically acceptable limits. Discussion: Unlike traditional metaheuristics such as PSO or GA, which are less suited for constraint-rich, dynamic ODE-based systems, ADϵSA offers structural advantages in trajectory feasibility and adaptive convergence. This study highlights the potential of biologically informed optimization algorithms in personalized oncology and provides a computational basis for future closed-loop, patient-specific treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.